NCT07432295 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07432295
Title	Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Acronym	GIVA-2
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	I-Mab Biopharma US Limited
Indications	gastroesophageal junction adenocarcinoma gastric adenocarcinoma esophagus adenocarcinoma
Therapies	Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Fluorouracil + Givastomig + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Capecitabine + Givastomig + Nivolumab + Oxaliplatin
Age Groups:	senior \| adult
Covered Countries	USA

Additional content available in CKB BOOST